The Breast Cancer Program at the University of Southern California (USC)/Norris Comprehensive Cancer Center (NCC) is a focused interdisciplinary research program devoted to breast cancer. The scientific aims of the program are 1) to Test hypotheses of breast cancer etiology and pathogenesis with a particular emphasis on diverse racial/ethnic groups within Los Angeles County, 2) To identify differences in breast cancer mortality among racial ethnic groups of Los Angeles County and formulate strategies to lower mortality among all groups. 3) To characterize molecular genetic alterations in breast cancers with a focus on potential clinical utility, 4) To formulate and assess various strategies for breast cancer prevention, and 5) To develop and/or evaluate novel therapies for breast cancer; to enroll patients on local or national therapeutic protocols related to breast cancer, particularly emphasizing minority patient recruitment. The USC/Norris Breast Cancer Program takes advantage of the extraordinary, racial-ethic diversity among the 10 million residents of Los Angeles County, the population served by the NCCC. A major goal of the Program is to better understand the reasons for the underlying differences in breast cancer incidence, mortality and survival among the numerically most important of these racial-ethnic groups in the County (African-Americans, Latinas, Japanese, Chinese, Filipinas, Koreans and non-Latina whites). We have a multifaceted approach involving epidemiology and prevention scientists, behavioral scientists, tumor biologists and molecular geneticists, and radiation surgical and medical oncologists. Numerous patient and data resources are used to achieve this goal. These include the Los Angeles County SEER cancer registry program; a registry of breast cancer in twins; dietary and lifestyle data from recently characterized large racial- ethnically diverse cohorts; a large and diverse clinical population seen at NCCC affiliated hospitals; and several large tumor and other biological sample banks for studies of tumor biology and molecular genetics. The integrated multi-disciplinary Lee Breast Center has been built in the Hospital providing an environment favorable to patient care and clinical research. Recruitment of study subjects to clinical investigations has been strengthened during the last funding period. The overall annual research budget for the Program is in excess of $7 million. Four members of the Breast Cancer Program have been named to endowed Chairs in the NCCC. Funding has been provided for recruitment of new faculty, an annual program retreat, pilot research projects, and startup research funds for recruited faculty.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014089-27S1
Application #
6577728
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-04-02
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications